Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other.

Slides:



Advertisements
Similar presentations
K. Brennan, J.L. Koenig, A.J. Gentles, J.B. Sunwoo, O. Gevaert
Advertisements

Inhibition of SOX17 by MicroRNA 141 and Methylation Activates the WNT Signaling Pathway in Esophageal Cancer  Yan Jia, Yunsheng Yang, Qimin Zhan, Malcolm.
From: Epigenetic instability of imprinted genes in human cancers
Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other.
Ane Y. Schmidt, Thomas v. O. Hansen, Lise B
Comparison of Clinical Targeted Next-Generation Sequence Data from Formalin-Fixed and Fresh-Frozen Tissue Specimens  David H. Spencer, Jennifer K. Sehn,
FMR1 Intron 1 Methylation Predicts FMRP Expression in Blood of Female Carriers of Expanded FMR1 Alleles  David E. Godler, Howard R. Slater, Quang M. Bui,
A Strategy to Find Suitable Reference Genes for miRNA Quantitative PCR Analysis and Its Application to Cervical Specimens  Iris Babion, Barbara C. Snoek,
Diego M. Marzese, Dave S. B. Hoon, Kelly K. Chong, Francisco E
A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors  Rajyalakshmi.
Assessing Copy Number Alterations in Targeted, Amplicon-Based Next-Generation Sequencing Data  Catherine Grasso, Timothy Butler, Katherine Rhodes, Michael.
The Functional Impact of Alternative Splicing in Cancer
CDKN2A/p16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Non–Small-Cell Lung Cancer  Kit W. Tam, MD, MHS,
A Method to Evaluate the Quality of Clinical Gene-Panel Sequencing Data for Single- Nucleotide Variant Detection  Chung Lee, Joon S. Bae, Gyu H. Ryu, Nayoung.
Molecular Signatures for Tumor Classification
Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation  Martin Lauss, Rizwan Haq, Helena Cirenajwis,
Volume 133, Issue 6, Pages (December 2007)
Genome-Wide Identification and Validation of a Novel Methylation Biomarker, SDC2, for Blood-Based Detection of Colorectal Cancer  TaeJeong Oh, Nayoung.
Separate Quality-Control Measures Are Necessary for Estimation of RNA and Methylated DNA from Formalin-Fixed, Paraffin-Embedded Specimens by Quantitative.
Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic.
The Clinical Implications of Inconsistently Methylated Results from Glioblastoma MGMT Testing by Replicate Methylation-Specific PCR  Daniel Xia, David.
Improving Mutation Screening in Patients with Colorectal Cancer Predisposition Using Next-Generation Sequencing  Jean-Marc Rey, Vincent Ducros, Pascal.
A Diagnostic Assay Based on MicroRNA Expression Accurately Identifies Malignant Pleural Mesothelioma  Hila Benjamin, Danit Lebanony, Shai Rosenwald, Lahav.
HIC1 Expression Distinguishes Intestinal Carcinomas Sensitive to Chemotherapy  Lucie Janeckova, Michal Kolar, Jiri Svec, Lucie Lanikova, Vendula Pospichalova,
Inhibition of SOX17 by MicroRNA 141 and Methylation Activates the WNT Signaling Pathway in Esophageal Cancer  Yan Jia, Yunsheng Yang, Qimin Zhan, Malcolm.
Angela Leo, Andrew M. Walker, Matthew S
Validation of Real-Time Methylation-Specific PCR to Determine O6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation in Glioma  Ilse Vlassenbroeck,
Comparison of High-Resolution Melting Analysis, TaqMan Allelic Discrimination Assay, and Sanger Sequencing for Clopidogrel Efficacy Genotyping in Routine.
Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival  Ryan K. Van Laar 
Christopher R. Cabanski, Vincent Magrini, Malachi Griffith, Obi L
Comparative Genomic Hybridization Analysis of Astrocytomas
A Tumor Sorting Protocol that Enables Enrichment of Pancreatic Adenocarcinoma Cells and Facilitation of Genetic Analyses  Zachary S. Boyd, Rajiv Raja,
Robust Detection of DNA Hypermethylation of ZNF154 as a Pan-Cancer Locus with in Silico Modeling for Blood-Based Diagnostic Development  Gennady Margolin,
The History and Impact of Molecular Coding Changes on Coverage and Reimbursement of Molecular Diagnostic Tests  Susan J. Hsiao, Mahesh M. Mansukhani,
A Rapid and Sensitive Next-Generation Sequencing Method to Detect RB1 Mutations Improves Care for Retinoblastoma Patients and Their Families  Wenhui L.
Volume 23, Issue 11, Pages (June 2018)
QuantiGene Plex Represents a Promising Diagnostic Tool for Cell-of-Origin Subtyping of Diffuse Large B-Cell Lymphoma  John S. Hall, Suzanne Usher, Richard.
Kyong-Ah Yoon, Sohee Park, Sang Hee Lee, Jin Hee Kim, Jin Soo Lee 
Volume 26, Issue 4, Pages (October 2014)
Brian K. Maples, Simon Gravel, Eimear E. Kenny, Carlos D. Bustamante 
SNPitty The Journal of Molecular Diagnostics
Cyclin E1 Is Amplified and Overexpressed in Osteosarcoma
Rapid Next-Generation Sequencing Method for Prediction of Prostate Cancer Risks  Viacheslav Y. Fofanov, Kinnari Upadhyay, Alexander Pearlman, Johnny Loke,
The Functional Impact of Alternative Splicing in Cancer
Volume 4, Issue 3, Pages (August 2013)
Kelsie L. Thu, BSc, Raj Chari, PhD, William W
Olivier Gruselle, Thierry Coche, Jamila Louahed 
S. Hussain Askree, Shika Dharamrup, Lawrence N. Hjelm, Bradford Coffee 
Epigenetic regulation of miR-193b in liposarcomagenesis.
Development of a Diagnostic Microarray Assay to Assess the Risk of Recurrence of Prostate Cancer Based on PITX2 DNA Methylation  Philipp Schatz, Dimo.
Detailed Characterization of Alterations of Chromosomes 7, 9, and 10 in Glioblastomas as Assessed by Single-Nucleotide Polymorphism Arrays  Inês Crespo,
Serum DNA Motifs Predict Disease and Clinical Status in Multiple Sclerosis  Julia Beck, Howard B. Urnovitz, Marina Saresella, Domenico Caputo, Mario Clerici,
Volume 23, Issue 1, Pages 9-22 (January 2013)
Diego M. Marzese, Dave S. B. Hoon, Kelly K. Chong, Francisco E
Defining Ploidy-Specific Thresholds in Array Comparative Genomic Hybridization to Improve the Sensitivity of Detection of Single Copy Alterations in Cell.
Inhibition of SOX17 by MicroRNA 141 and Methylation Activates the WNT Signaling Pathway in Esophageal Cancer  Yan Jia, Yunsheng Yang, Qimin Zhan, Malcolm.
DNA and RNA References for qRT-PCR Assays in Exfoliated Cervical Cells
Remco van Doorn, Willem H. Zoutman, Nelleke A. Gruis 
A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer  Zengliu Su, Dora Dias-Santagata,
Epigenetic Control of the S100A6 (Calcyclin) Gene Expression
James M. Flanagan, Sibylle Cocciardi, Nic Waddell, Cameron N
Dara S. Ross, Ahmet Zehir, Donavan T
Nathan D. Montgomery, Sara R. Selitsky, Nirali M. Patel, D
Complex History of Admixture between Modern Humans and Neandertals
Pleiotropic Effects of Trait-Associated Genetic Variation on DNA Methylation: Utility for Refining GWAS Loci  Eilis Hannon, Mike Weedon, Nicholas Bray,
Evaluation of Markers for CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer by a Large Population-Based Sample  Shuji Ogino, Takako Kawasaki,
Practical Bioinformatic DNA-Sequencing Pipeline for Detecting Oncogene Amplification and EGFRvIII Mutational Status in Clinical Glioblastoma Samples 
The History and Impact of Molecular Coding Changes on Coverage and Reimbursement of Molecular Diagnostic Tests  Susan J. Hsiao, Mahesh M. Mansukhani,
Gene expression patterns of SLC and ABC transporters in normal and tumor tissues. Gene expression patterns of SLC and ABC transporters in normal and tumor.
Collin Tokheim, Rachel Karchin  Cell Systems 
Presentation transcript:

Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors  Pierre Bady, Mauro Delorenzi, Monika E. Hegi  The Journal of Molecular Diagnostics  Volume 18, Issue 3, Pages 350-361 (May 2016) DOI: 10.1016/j.jmoldx.2015.11.009 Copyright © 2016 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

Figure 1 Spatial correlation between MGMT expression and CpG methylation in the MGMT promoter. The correlation between the Infinium probes, in the MGMT promoter (genome assembly 37, hg19) present on the Inifinium HM-450K and the 27K BeadChip, respectively, and expression of MGMT is displayed for five glioma data sets (AFFYmetrix probe; RNA sequencing for TCGA-Glioma II/III). The black, green, and red lines correspond to the correlation for all samples, CIMP−, and CIMP+ populations, respectively. The CpG island located in the MGMT promoter region is illustrated with a green bar, and the location of the two Inifinium HM-450K/27K probes used in the model MGMT-STP27 are indicated with dark blue marks, and the TSS with an arrow. CIMP, CpG island methylator phenotype; CIMP+, presence of CIMP; CIMP−, absence of CIMP; GBM, glioblastoma; TCGA, The Cancer Genome Atlas; TSS, transcription start site. The Journal of Molecular Diagnostics 2016 18, 350-361DOI: (10.1016/j.jmoldx.2015.11.009) Copyright © 2016 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

Figure 2 Distribution of the MGMT scores in glioma grade II to IV stratified by CIMP status. The density plots of the MGMT scores, corresponding to the logit-transformed probabilities (MGMT score) that the MGMT promoter is methylated, are shown for the LGG (grade II and III) and GBM (grade IV) populations. The solid lines are provided by kernel density estimate, and indicate in green grade IV (GBM), in red grade III, and in blue grade II glioma. The vertical dotted lines identify the position of the cutoff used to classify into methylated and unmethylated MGMT promoter status. CIMP, CpG island methylator phenotype; GBM, glioblastoma; LGG, low-grade glioma; TCGA, The Cancer Genome Atlas. The Journal of Molecular Diagnostics 2016 18, 350-361DOI: (10.1016/j.jmoldx.2015.11.009) Copyright © 2016 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

Figure 3 Distribution of MGMT score for nonglioma data sets from TCGA. The score corresponds to the logit-transformed probabilities that the MGMT promoter is methylated. The black solid line is provided by kernel density estimate. The vertical dotted line identifies the position of the cutoff used to determinate the MGMT promoter state.11 The proportion of MGMT methylation for TCGA-HNSC is 138 of 442 (31.2%; 95% CI, 26.9%–35.8%), 53 of 328 (16%; 95% CI, 12.3%–20.6%) for TCGA-LUSC, 13 of 305 (4.3%; 95% CI, 2.3%–7.2%) for TCGA-BRCA, and 83 of 227 (36.6%; 95% CI, 3.0%–4.3%) for TCGA-COAD. BRCA, breast carcinoma; CI, confidence interval; COAD, colon adenocarcinoma; HNSC, head and neck squamous cell carcinoma; LUSC, lung squamous cell carcinoma; TCGA, The Cancer Genome Atlas. The Journal of Molecular Diagnostics 2016 18, 350-361DOI: (10.1016/j.jmoldx.2015.11.009) Copyright © 2016 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

Figure 4 Boxplot representation of MGMT expression in function of CNA and MGMT methylation status in glioma grade II to IV. For each data set the number of samples for each subpopulation is provided next to the box. Subpopulations of del are indicated in white and no-del in black. CNA, copy number alteration; del, deletion at 10q26.3; M, MGMT methylated; no-del, subpopulations with normal copy number; U, MGMT unmethylated. The Journal of Molecular Diagnostics 2016 18, 350-361DOI: (10.1016/j.jmoldx.2015.11.009) Copyright © 2016 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

Figure 5 Effect of data preprocessing procedures on MGMT classification. Paired comparisons of the probabilities of MGMT promoter methylation (MGMT-STP27) between preprocessing procedures for the M-GBM data set. Five preprocessing procedures for the HM-450K platform were compared with the initial procedure used to build the model MGMT-STP27. The outputs from recommended preprocessing were compared with outputs from the Illumina-like procedure that was based on control normalization (a reference sample was used during the normalization step) (A), preprocessing with Illumina-like background correction only (B), quantile normalization (C), SWAN normalization (D), and NOOB normalization (E). Each data set contained exactly the same samples. The gray dashed lines identify the original cutoff of 0.3582. The straight, dashed black line corresponds to the equation y = x, and the gray line to the loess regression, respectively. The proportions of good classification (DA) are provided for the original cutoff on each panel. DA, diagnostic accuracy; GBM, glioblastoma; M-GBM, training data set; MGMT, O(6)-methylguanine-DNA methyltransferase; NOOB, normal-exponential deconvolution; SWAN, subset-quantile within array normalization. The Journal of Molecular Diagnostics 2016 18, 350-361DOI: (10.1016/j.jmoldx.2015.11.009) Copyright © 2016 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

Figure 6 Quality control visualization for multisample and single sample predictions from R package mgmtstp27. The M-values of the two probes cg12434587 and cg12981137 are illustrated for multisample (A) and single sample (D) prediction. The inertia ellipses identify the training data set (M-GBM) and the dots correspond to the location of the new sample prediction. The red and blue colors visualize methylated (M) and unmethylated (U) status, respectively. B: The comparison of the MGMT score distribution of a new multisample data set TCGA-GBM-27 (black curve) with the training data set (M-GBM, green curve, histogram). For single sample prediction, the new sample is indicated by the black vertical line (E). C: The multisample predictions (MGMT score and probabilities) for the data set TCGA-GBM-27 (black points and lines) associated with their prediction intervals (gray polygons). F: The prediction for the sample TCGA-02-0057 from the data set TCGA-GBM-27 associated with the prediction interval. As reference, the green curve and gray polygons correspond to the prediction and CIs for M-GBM. CI, confidence interval; GBM, glioblastoma; M, MGMT methylated; TCGA, The Cancer Genome Atlas; U, MGMT unmethylated. The Journal of Molecular Diagnostics 2016 18, 350-361DOI: (10.1016/j.jmoldx.2015.11.009) Copyright © 2016 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions